Teva Pharmaceutical Industries Shares Outstanding 2006-2018 | TEVA

Current and historical number of shares outstanding for Teva Pharmaceutical Industries (TEVA) from 2006 to 2018. Diluted shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options.
Teva Pharmaceutical Industries Annual Shares Outstanding
(Millions of US $)
2017 $1,016
2016 $961
2015 $864
2014 $858
2013 $850
2012 $873
2011 $893
2010 $921
2009 $896
2008 $820
2007 $830
2006 $805
2005 $681
Teva Pharmaceutical Industries Quarterly Shares Outstanding
(Millions of US $)
Q2 2018 $1,018
Q1 2018 $1,020
Q4 2017 $1,016
Q3 2017 $1,017
Q2 2017 $1,017
Q1 2017 $1,017
Q4 2016 $961
Q3 2016 $984
Q2 2016 $920
Q1 2016 $920
Q4 2015 $864
Q3 2015 $862
Q2 2015 $859
Q1 2015 $859
Q4 2014 $858
Q3 2014 $861
Q2 2014 $857
Q1 2014 $852
Q4 2013 $850
Q3 2013 $846
Q2 2013 $849
Q1 2013 $856
Q4 2012 $873
Q3 2012 $869
Q2 2012 $873
Q1 2012 $882
Q4 2011 $893
Q3 2011 $890
Q2 2011 $896
Q1 2011 $902
Q4 2010 $921
Q3 2010 $921
Q2 2010 $921
Q1 2010 $921
Q4 2009 $900
Q3 2009 $915
Q2 2009 $895
Q1 2009 $894
Q4 2008 $785
Q3 2008 $837
Q2 2008 $836
Q1 2008 $817
Q4 2007 $834
Q3 2007 $832
Q2 2007 $828
Q1 2007 $827
Q4 2006 $832
Q3 2006 $834
Q2 2006 $834
Q1 2006 $722
Q4 2005 $682
Q3 2005 $678
Q2 2005 $678
Q1 2005 $682
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $22.849B $22.385B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.621B 10.74
Mylan (MYL) United Kingdom $19.499B 8.29
Bausch Health Cos (BHC) Canada $7.285B 5.44
Dr Reddy's Laboratories (RDY) India $5.340B 23.85
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.698B 4.59
Akorn (AKRX) United States $2.422B 11.99
Supernus Pharmaceuticals (SUPN) United States $2.258B 24.16
Assembly Biosciences (ASMB) United States $0.913B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.809B 116.67
CymaBay Therapeutics (CBAY) United States $0.706B 0.00
Homology Medicines (FIXX) United States $0.622B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.604B 0.00
Voyager Therapeutics (VYGR) United States $0.593B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.590B 0.00
Corium (CORI) United States $0.319B 0.00
Teligent (TLGT) United States $0.225B 0.00
Sol-Gel Technologies (SLGL) Israel $0.118B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.111B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.067B 0.00
Aevi Genomic Medicine (GNMX) United States $0.066B 0.00
Versartis (VSAR) United States $0.062B 0.00
Evoke Pharma (EVOK) United States $0.039B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.022B 0.00
Acasti Pharma (ACST) Canada $0.017B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00